Response to crizotinib in a lung adenocarcinoma patient harboring EML4-ALK translocation with adnexal metastasis: A Case Report

BACKGROUND: Lung cancer with ovarian metastasis or adnexal metastasis harboring anaplastic lymphoma kinase (ALK) gene translocation is rare. Crizotinib, a novel ALK tyrosine kinase inhibitor, has already shown an impressive single-agent activity in ALK positive lung cancer. METHODS: To summarize the...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Wenxian, Wu, Wei, Zhang, Yiping
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2016
Materias:
5700
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5265830/
https://www.ncbi.nlm.nih.gov/pubmed/27472693
http://dx.doi.org/10.1097/MD.0000000000004221

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5265830/
https://www.ncbi.nlm.nih.gov/pubmed/27472693
http://dx.doi.org/10.1097/MD.0000000000004221

Ejemplares similares